| Grifols–Shanghai RAAS: plasma products + diagnostics, 201911c– strategic alliance in China incl share swap |
2019-11-13 |
| Shanghai RAAS–Grifols: investment, 201911c acquisition 26.2% share in Shanghai RAAS via share swap as part of strategic alliance |
2019-11-13 |
| i-Dositecno–SP Industries: investment, 201910 acquisition of assets of i-Dositecno by SP Industries |
2019-10-28 |
| SP Industries–i-Dositecno: filling solutions, 201908– collab product integration to offer complete aseptic vial/syringe fill-finish lines |
2019-08-13 |
| Infarco–Keensight Capital: investment, 201907 acquisition of Infarco’s majority stake in 3P Biopharmaceuticals by Keensight |
2019-07-23 |
| Sanifit–Alta Life Sciences: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Alta Life Sciences |
2019-06-26 |
| Sanifit–Andera Partners: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Andera Partners |
2019-06-26 |
| Sanifit–Columbus Venture Partners: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Columbus Venture Partners |
2019-06-26 |
| Sanifit–Consilium: public relations, 201906 service existent by CSC |
2019-06-26 |
| Sanifit–Forbion: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Forbion Capital Partners |
2019-06-26 |
| Sanifit–Gilde Investment: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Gilde Healthcare |
2019-06-26 |
| Sanifit–HealthEquity: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor HealthEquity |
2019-06-26 |
| Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc |
2019-06-26 |
| Sanifit–Lundbeck: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Lundbeckfonden Ventures |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906 financing round Series D €55.2m led by Caixa Capital Risc |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906c capitalisation of €17m of convertible bonds |
2019-06-26 |
| Sanifit–Ysios Capital: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Ysios Capital |
2019-06-26 |
| Ona Therapeutics–Asabys Partners: investment, 201905 seed financing €1.5m from Sabadell Asabys Fund |
2019-05-21 |
| Adrenomed–Informa: investor conference, 201905 supply service Adrenomed presents at BioEquity Europe 2019 in Barcelona |
2019-05-20 |
| Devicare–SEVERAL: investment, 201905– crowdfunding compaign via Capital Cell platform |
2019-05-06 |
| Diem Labs–Devicare: medical device, 201905– collab marketing of Lit-Control in the US by Diem Labs LLC |
2019-05-03 |
| SOM Biotech–SEVERAL: investment, 201903 financing round €7m led by European family holding |
2019-03-07 |
| Grifols–Rigel: fostamatinib, 201901– collab + license $30m upront + $297.5m milestones + royalties all indications in Europe + Turkey |
2019-01-23 |
| Senolytic Therapeutics–Life Biosciences: investment, 201901 acquisition of Senolytic by Life Biosciences |
2019-01-09 |
| Melio Health–Kanoar Ventures: investment, 2019c seed financing round for IMU Biosciences incl investor Kfund |
2019-01-01 |
| Mestrelab Research–Bruker: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership |
2018-12-13 |
| Oryzon Genomics–Citigroup: investor conference, 201812 supply service Oryzon attends Citi Global Healthcare Conference NY |
2018-12-05 |
| Oryzon Genomics–Leucadia: investor conference, 201811 supply service Oryzon attends Jefferies London Healthcare Conference 2018 |
2018-11-14 |
| Galecto–Ysios Capital: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor Ysios Capital |
2018-10-26 |
| Oryzon Genomics–SEVERAL: investment, 201810 private placement €13m w 4.96m new common shares at €2.62/share |
2018-10-26 |
| Minoryx–SEVERAL: investment, 201809 financing round Series B €21.3m led by Fund+ with SFPI + SRIW + Sambrinvest + all Series A investors |
2018-09-26 |
| Almirall–Evotec: drug discovery services, 201809– collab RnD therapies for dermatological diseases |
2018-09-17 |
| Grifols–EU (govt): credit, 201809–2028 loan €85m from European Investment Bank |
2018-09-07 |
| Molecular Discovery–Lead Molecular Design: mass spectrometry s/w, 201808 distribution existent of MetaSite + MassMetaSite et al by Molecular Discovery |
2018-08-04 |
| Laboratorios Ecosur–Eurofins: investment, 201807 acquisition of Ecosur by Eurofins |
2018-07-27 |
| Sanifit–PNC Financial Services: investor conference, 201807 supply service Sanifit presents at 2018 European Biotech Investor Day in NYC |
2018-07-19 |
| Pharma Omnium–NuPharm: investment, 201807 acquisition €na of Laboratoire Biodim from Pharma Omnium |
2018-07-03 |
| Algenex–Cleon Capital: investment, 201807–201903 financing round Series B totalling €4m incl co-lead investor Cleon Capital |
2018-07-01 |
| Algenex–SEVERAL: investment, 201807–201903 financing round Series B €4m led by Cleon Capital + Vita Advisory |
2018-07-01 |
| Algenex–VitaTech: investment, 201807–201903 financing round Series B totalling €4m incl co-lead investor Vita Advisory |
2018-07-01 |
| Lunaphore–Vitro (ES): in situ hybridisation, 201805– collab developm ISH protocols for RNA + DNA targets in tissue |
2018-05-24 |
| Bionure–Alta Life Sciences: investment, 201805 financing round Series A totalling €4m incl lead investor Alta Life Sciences |
2018-05-16 |
| Bionure–SEVERAL: investment, 201805 financing round Series A €4m led by Alta Life Sciences |
2018-05-16 |
| Paralab (PT)–Applied Photophysics: analytical instruments, 201805– distribution of Chirascan CD + SX stoppe-flow systems in ES +PT by Paralab |
2018-05-15 |
| Reig Jofré–LeanBio: biosimilars, 201803– collab founding of joint venture Syna Therapeutics to develop biosimilars |
2018-03-23 |
| Aton–Grifols: investment, 201803– acquisition 100% of Haema for €220 on a debt free basis by Grifols from Aton GmbH |
2018-03-20 |
| ABAC Therapeutics–SEVERAL: investment, 201802 financing round Series A €16m led by Pontifax + incl GHSF + Caixa Capital Risc + Debiopharm + Ferrer |
2018-02-15 |
| STAT-Diagnostica–Qiagen: investment, 201801 acquisition $147m upfront cash + $44m milestones of STAT-Dx by Qiagen |
2018-01-31 |
| Intelligent Pharma–Mind the Byte: investment, 201801 acquisition €na 100% of Intelligent Pharma by Mind the Byte |
2018-01-11 |
| Mind the Byte–SEVERAL: investment, 201801– financing round €3m (1/3 of company) to finance acquisition of Intelligent Pharma PLANNED |
2018-01-11 |
| Ahead Therapeutics–SEVERAL: investment, 2018 funding total private investment attracted Jan to May 2018 |
2018-01-01 |
| Elma Care–SEVERAL: investment, 2018 funding total private investment attracted Jan to May 2018 |
2018-01-01 |
| Mediquo–SEVERAL: investment, 2018 funding total private investment attracted Jan to May 2018 |
2018-01-01 |
| ProteoDesign–SEVERAL: investment, 2018 funding total private investment attracted Jan to May 2018 |
2018-01-01 |
| Grifols–EU (govt): credit, 201712– loan €85m from European Investment Bank |
2017-12-05 |
| CLINGLIO project–EU (govt): grant, 201712–202011 Horizon 2020 grant €6.15m 3y for ph2 trial of 2OHOA in malignant glioma |
2017-12-01 |
| Mind the Byte–Prosilico: drug discovery + development software, 201711– collab co-promotion + product integration |
2017-11-15 |
| Mestrelab Research–SpectralWorks: analytical instrument software, 201708– collab mutual reseller agreem for all respective NMR/MS s/w products |
2017-08-15 |
| GigaGen–Grifols: investment, acquisition of 44% stake in GigaGen Inc for $35m in cash by Grifols |
2017-07-05 |
| FB Health–Invent Farma/Neuraxpharm: investment, 201706 acquisition €na of FB Health by Invent Farma/Neuraxpharm (formed 8/16 by Apax Partners) |
2017-06-21 |
| Oryzon Genomics–JMP Securities: investor conference, 201706 supply service Oryzon at JMP Securities 2017 Life Sciences Conference NY |
2017-06-20 |
| Oryzon Genomics–Leucadia: investor conference, 201706 supply service Oryzon presents at Jefferies Healthcare Conference in New York |
2017-06-09 |
| Celgene–IMIDomics: anti-inflammatory drugs, 201705– strategic collab r+d treatments for immune-mediated inflammatory diseases (IMIDs) |
2017-05-31 |
| Oryzon Genomics–Trout Group: public relations, 201705 service existent investor relations by Trout Group |
2017-05-31 |
| AptaTargets–Inveready: investment, 201705 financing round totalling €2.7m from Caixa Capital Risc + Inveready |
2017-05-17 |
| AptaTargets–la Caixa: investment, 201705 financing round totalling €2.7m from Caixa Capital Risc + Inveready |
2017-05-17 |
| AptaTargets–SEVERAL: investment, 201705 financing round €2.7m from Caixa Capital Risc + Inveready |
2017-05-17 |
| Specialised Therapeutics Australia–PharmaMar: lurbinectedin, 201705– license to market lurbinectedin in AU + NZ + 12 Asian countries for STA |
2017-05-17 |
| Mind the Byte–SEVERAL: investment, 201705–201707 financing round €300k via crowdfunding platform Crowdcube |
2017-05-09 |
| Vivet Therapeutics–Columbus Venture Partners: investment, 201705 financing round Series A totalling €37.5m incl co-lead investor CVP |
2017-05-04 |
| Vivet Therapeutics–Ysios Capital: investment, 201705 financing round Series A totalling €37.5m incl co-investor Ysios Capital |
2017-05-04 |
| Oryzon Genomics–SEVERAL: investment, 201703 private placement €18.2m w 5.7m news common shares at €3.2/share |
2017-03-31 |
| BioClin Therapeutics–Ysios Capital: investment, 201703 financing round Series B totalling $30m led by new investors Sofinnova Ventures + Ysios Capital |
2017-03-22 |
| Imegen (ES)–SEVERAL: investment, 201703 acquisition €10m of majority share in Imegen by Q-Growth Fund + Biolty |
2017-03-16 |
| MedLumics–LCF Rothschild: investment, 201703 investment by EdRIP |
2017-03-01 |
| BioSequence (ES)–OncoDNA: investment, 201702 acquisition €na of BioSequence by OncoDNA |
2017-02-13 |
| Prexton Therapeutics–Ysios Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Ysios Capital |
2017-02-07 |
| Anaconda Biomed–SEVERAL: investment, 2017 funding €15m total private investment attracted over the year 2017 |
2017-01-01 |
| Bionure–SEVERAL: investment, 2017 funding €1.2m total private investment attracted over the year 2017 |
2017-01-01 |
| Bwom Technologies–SEVERAL: investment, 2017 funding €1m total private investment attracted over the year 2017 |
2017-01-01 |
| Devicare–SEVERAL: investment, 2017 funding €5m total private investment attracted over the year 2017 |
2017-01-01 |
| Glycardial Diagnostics–SEVERAL: investment, 2017 funding €2.4m total private investment attracted over the year 2017 |
2017-01-01 |
| iMicroQ–SEVERAL: investment, 2017 funding €1.5m total private investment attracted over the year 2017 |
2017-01-01 |
| Inkemia IUCT–SEVERAL: investment, 2017 funding €2.2m total private investment attracted over the year 2017 |
2017-01-01 |
| Linkcare–SEVERAL: investment, 2017 funding €5m total private investment attracted over the year 2017 |
2017-01-01 |
| Peptomyc–SEVERAL: investment, 2017 funding €4.4m total private investment attracted over the year 2017 |
2017-01-01 |
| Qmenta–SEVERAL: investment, 2017 funding €2.7m total private investment attracted over the year 2017 |
2017-01-01 |
| SOM Biotech–SEVERAL: investment, 2017 funding €2m total private investment attracted over the year 2017 |
2017-01-01 |
| Top Doctors–SEVERAL: investment, 2017 funding €3m total private investment attracted over the year 2017 |
2017-01-01 |
| Transmural Biotech–SEVERAL: investment, 2017 funding €2.7m total private investment attracted over the year 2017 |
2017-01-01 |
| Transplant Biomedicals–SEVERAL: investment, 2017 funding €8.5m total private investment attracted over the year 2017 |
2017-01-01 |
| Villapharma Research–Eurofins: investment, 201612– acquisition of Villapharma by Eurofins ANNOUNCED |
2016-12-29 |
| CorWave–Ysios Capital: investment, 201611 financing round Series B totalling €15.5m incl new + co-investor Ysios Capital |
2016-11-04 |
| Iproteos–SEVERAL: investment, 201610 financing round €1.5m led by Caixa Capital Risc + co-investors Kinled Holding + Ascil Biopharm |
2016-10-25 |
| AB-Biotics–SEVERAL: investment, 2016 funding €11.7m total private investment attracted over the year 2016 |
2016-01-01 |
| Albajuna Therapeutics–SEVERAL: investment, 2016 funding €3.75m total private investment attracted over the year 2016 |
2016-01-01 |
| Bioprognos–SEVERAL: investment, 2016 funding €1m total private investment attracted over the year 2016 |
2016-01-01 |
| Cebiotex–SEVERAL: investment, 2016 funding €1.8m total private investment attracted over the year 2016 |
2016-01-01 |
| Corino Therapeutics–SOM Biotech: CNS drug, 2016 license ww excl for developm + commercialisation of SOM0226 to treat TTR amyloidosis |
2016-01-01 |
| Cuantum Medical Cosmetics–SEVERAL: investment, 2016 funding €1.8m total private investment attracted over the year 2016 |
2016-01-01 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
